In France, cannabis is a widely used but illicit substance. Recently, products like CBD, dubbed "cannabis light" or "cannabis well-being, " have hit the market. Simultaneously, the medical cannabis experiment began in March 2021. Cannabis can have beneficial effects, but it also comes with risks like addiction and adverse health events (AEs). Data from addictovigilance (monitoring drug addiction and abuse) and international research has helped establish criteria for patients at risk, such as those with severe heart, kidney, or liver conditions, or mental health issues like psychotic disorders. This data allows for early detection of AEs. Medical cannabis contains CBD and/or THC in varying amounts.

Out of 3164 patients in the French experiment, 1186 experienced an AE. Some reported issues, like heart problems (heart attacks, strokes) and psychiatric issues (suicidal thoughts, depression), were also seen in non-medical cannabis use. Given the potential for addiction to cannabis meds, doctors need to know their patients' addiction history to prevent and detect any risks. A 2024 law allowed for wider medical cannabis use, with prescriptions for specific conditions. Close monitoring by addictovigilance and pharmacovigilance (drug safety) is crucial to keep medical cannabis accessible and safe. Doctors need to be aware of potential neurological, psychiatric, and cardiovascular issues and unexpected AEs.

Exploring CBD and THC in France: Lessons from Addictovigilance Data

Actions